Iksuda Therapeutics

Leading South Korean antibody-drug conjugate (ADC) specialist LigaChem Biosciences has made a $25m investment for an initial 26.6% equity stake in existing partner IKSUDA Therapeutics, and secured the

Celltrion Group is moving forward with business plans to diversify into the development of its own new drugs, showcasing early data on several antibody-drug conjugate (ADC) candidates. The South Korea

Celltrion Group is moving forward with business plans to diversify into the development of its own new drugs, showcasing early data on several antibody-drug conjugate (ADC) candidates. The South Korea

Drug delivery technologies will continue to be a main theme for the Korean biopharma industry in 2024. Amid a tougher environment to develop innovative therapies, more companies may prioritize develop